Macrocure (MCUR) vs. The Competition Head to Head Analysis
Macrocure (NASDAQ: MCUR) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Macrocure to related companies based on the strength of its risk, profitability, valuation, analyst recommendations, dividends, institutional ownership and earnings.
This is a summary of current recommendations for Macrocure and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 22.34%. Given Macrocure’s competitors higher possible upside, analysts clearly believe Macrocure has less favorable growth aspects than its competitors.
Valuation & Earnings
This table compares Macrocure and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Macrocure Competitors||$2.57 billion||$977.16 million||2.89|
Macrocure’s competitors have higher revenue and earnings than Macrocure. Macrocure is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
2.8% of Macrocure shares are held by institutional investors. Comparatively, 66.4% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Volatility & Risk
Macrocure has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Macrocure’s competitors have a beta of 0.81, indicating that their average share price is 19% less volatile than the S&P 500.
This table compares Macrocure and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Macrocure competitors beat Macrocure on 5 of the 8 factors compared.
Macrocure Company Profile
Leap Therapeutics Ltd, formerly Macrocure Ltd, is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell is in Phase III. Its CureXcell addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body’s natural healing process. Its delivery method of direct superficial injection into the chronic wound allows the precise delivery of the cells into the defective wound tissue where they can be effective.
Receive News & Ratings for Macrocure Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Macrocure Ltd and related companies with MarketBeat.com's FREE daily email newsletter.